Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Oxford Biomedica

Request full access

Viral vector development and manufacturing for therapies

Oxford, United KingdomFounded 1995Biotech & Life Sciences

About Oxford Biomedica

Oxford Biomedica (OXB) is a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company was founded in 1995 as a spin-out from the University of Oxford by Professor Alan Kingsman and Dr. Susan Kingsman, leveraging their expertise in virology and gene expression. It went public via an initial public offering on the Alternative Investment Market in 1996.

OXB operates on a business-to-business (B2B) model, serving pharmaceutical and biotechnology companies ranging from small startups to large corporations. The company's core business revolves around providing viral vector development and manufacturing services, which are crucial components for its clients' gene and cell therapy products. This includes expertise in lentivirus, adeno-associated virus (AAV), and adenovirus vectors. Its revenue is generated through these contract services, supporting clients from early-stage development and clinical trials to full-scale commercial manufacturing. The company has recently transformed into a 'pure-play' CDMO to focus entirely on these client-centric services, a move that included significant operational streamlining.

The company's key offerings include its proprietary LentiVector™ platform and the inAAVate™ platform for AAV vectors, providing end-to-end solutions from process development to manufacturing. OXB has established numerous high-profile partnerships with companies like Novartis, Sanofi, and GSK. A notable collaboration was with the Jenner Institute and AstraZeneca to manufacture the COVID-19 vaccine. The company maintains state-of-the-art facilities in the UK, France, and the US to serve its global client base.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2008
Outcome tier
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Oxford Biomedica in the Oxford ecosystem

Live from Dealroom

The Oxford Biomedica office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later4 investors entered at this stage

  • Novo Ventures
  • Serum Institute of India
  • Transgene
  • Oaktree Capital Management
Team profiled 31 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
9 countries with
team presence
🇬🇧 United Kingdom70.2%
🇺🇸 United States14.7%
🇫🇷 France13.6%
🇩🇪 Germany0.5%
🇦🇺 Australia0.1%
Top 5 of 9 shown
Web traffic by country
24K monthly visits
across markets
🇬🇧 United Kingdom25.8%
🇺🇸 United States15.4%
🇮🇳 India6.7%
🇫🇷 France5.8%
🇪🇸 Spain2.5%
Top 5 markets shown

Patents

Estimated portfolio value
$16M

21 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Oxford Biomedica on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Oxford Biomedica on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.